MARKET WIREBenzinga • 6d ago
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $3Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $6 to $3.
Why NYXH Stock slipped -1.85% Today — RQD Quant Desk Flash
$0.87 -1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.87
Nyxoah SA (NYXH) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $88.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NYXH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NYXH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Nyxoah SA (NASDAQ: NYXH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.87 (-1.85% 1D, market cap $88.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NYXH ranks #416 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NYXH compare to LUCD and MBOT in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), NYXH carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, LUCD (Lucid Diagnostics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $87.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, NYXH leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NYXH?
▼
For Nyxoah SA (NYXH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #416 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.87 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NYXH)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY NYXH SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.5M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.31-27.5% Next Q
53
Q2 (-2Q)Grade C-$0.95-9.5% Next Q
50
Q3 (-1Q)Grade D$0.86+1.2% Next Q
48
CurrentGrade D$0.87-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NYXH Turnaround Squeeze
While NYXH currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.91) forces dealer call-delta covering toward $6.22.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NYXH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NYXH Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NYXH Stock slipped -1.85% Today — RQD Quant Desk Flash
Nyxoah SA (NYXH) slipped -1.85% to $0.87, trading at 2% of its 52-week range ($0.8 – $5.92). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.8 – $5.92) with RSI-14 at 31.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $0.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $2.5M annual free cash flow.
Live NYXH Headlines & Catalysts
MARKET WIREYahoo • 6d ago
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”
CATALYSTBenzinga • 10d ago
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving PremarketRingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
RISK WATCHYahoo • 11d ago
Nyxoah (ENXTBR:NYXH) Stock Sees Fair Value Falls After Q2 Analyst Target CutsNyxoah’s consensus fair value has shifted from about €5.80 to roughly €4.40, which is a reduction of close to one quarter in analyst price targets. This reset reflects recent Q2 updates, where some analysts remain encour
CATALYSTYahoo • 12d ago
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom FisherNyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in rev
MARKET WIREYahoo • 14d ago
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global preli
CATALYSTBenzinga • 14d ago
Nyxoah Reports Preliminary Q3 Global Net Sales Of ~€9.2M, Up 19% QoQ; Lowers FY26 Global Net Sales From €36M-€40M To €33M-€35MThird Quarter 2026 – Preliminary Sales and Market MetricsFinancialsGlobal net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NYXH)
- ✓Walkthrough of NYXH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NYXH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.79%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.90H $0.90L $0.87C $0.87VOL 178.8K
RES: $1.23SUP: $0.69SMA50: $1.33SMA200: $2.48
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NYXH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NYXH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NYXH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NYXH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NYXH)
Health Care Rank #416 of 1016
⚔️ LUCD vs NYXH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NYXH vs. LUCD, MBOT, QTEX, LNSR)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nyxoah SA (NYXH) ranks #416 by composite RQD confidence (45/100, grade D) and #677 by equity capitalization ($88.9M). Within this direct 5-issuer industry benchmark cohort, NYXH leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. LUCD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NYXH at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NYXH
ACTIVE
Nyxoah SA | D | 45/100 | — | — | — | -1.85% | $88.9M | Benchmark Subject |
| LUCD Lucid Diagnostics Inc. | D | 47/100 | — | — | -35.0% | -6.36% | $87.9M | /lucd-vs-nyxh → |
| MBOT Microbot Medical Inc. | D- | 41/100 | — | — | -15.8% | -2.68% | $75.2M | /mbot-vs-nyxh → |
| QTEX QTREX Quantum Ltd. | E | 31/100 | — | 0.7% | -35.0% | -7.58% | $73.9M | /qtex-vs-nyxh → |
| LNSR LENSAR Inc. | E | 24/100 | — | 39.4% | -35.0% | -2.18% | $73.3M | /lnsr-vs-nyxh → |
2. NYXH Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTNyxoah SA (NYXH) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $88.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. NYXH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NYXH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Nyxoah SA (NASDAQ: NYXH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.87 (-1.85% 1D, market cap $88.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NYXH ranks #416 in composite RQD confidence.
How does NYXH compare to LUCD and MBOT in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NYXH carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, LUCD (Lucid Diagnostics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $87.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, NYXH leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NYXH?
For Nyxoah SA (NYXH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #416 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NYXH trading relative to its 50-day, 200-day, and 52-week technical levels?
NYXH last traded at $0.87 (-1.85% on volume of 157,842 shares), positioning the stock -34.59% below its 50-day simple moving average ($1.33) and -64.92% below its 200-day simple moving average ($2.48). Across its 52-week range of $0.80 to $5.92, NYXH sits at the 1.4% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.00 to $0.96).
NYXH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NYXH stock moving today?
Why NYXH Stock slipped -1.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.